COVID-19 and SARS-CoV-2 antibodies in multiple sclerosis patients: a large study in the Amsterdam MS Cohort

COVID-19 and SARS-CoV-2 antibodies in multiple sclerosis patients: a large study in the Amsterdam MS Cohort - COMS-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49502

Enrollment

750

Registered

2020-07-28

Start date

2022-08-06

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS multiple sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Under current follow-up in the MS Center Amsterdam Current diagnosis of multiple sclerosis 18 years or older

Exclusion criteria

Exclusion criteria: No informed consent

Design outcomes

Primary

Measure	Time frame
Association of the course of COVID-19 and immunomodulatory treatment.	—

Secondary

Measure	Time frame
- establishing the percentage of MS patients who have currently developed SARS-CoV-2 antibodies in the Netherlands. - In the antibody positive patients we will associate disease course (asymptomatic, mild symptoms, severe symptoms, hospitalization) with MS characteristics, demographics and comorbidity. - Characteristics of patients with SARS-CoV-2 antibodies versus patients without antibodies in regards to demographics, MS characteristics, immunomodulatory treatments, prior medical history and degree of social isolation - With the Sanquin antibody test, we will study the antibody profile (IgM/G/A, IgG1/3) and repertoire (anti-SP, anti-NP).	—

Measure

Time frame

- establishing the percentage of MS patients who have currently developed SARS-CoV-2 antibodies in the Netherlands. - In the antibody positive patients we will associate disease course (asymptomatic, mild symptoms, severe symptoms, hospitalization) with MS characteristics, demographics and comorbidity. - Characteristics of patients with SARS-CoV-2 antibodies versus patients without antibodies in regards to demographics, MS characteristics, immunomodulatory treatments, prior medical history and degree of social isolation - With the Sanquin antibody test, we will study the antibody profile (IgM/G/A, IgG1/3) and repertoire (anti-SP, anti-NP).

—

Countries

Netherlands

Outcome results